Squamous cell carcinoma of head and neck
Not recruitingStudy of Retifanlimab, INCAGN02385, and INCAGN02390 for First-Line Treatment in Patients with PD-L1 Positive Recurrent/Metastatic Head and Neck Cancer
Study of Retifanlimab, INCAGN02385, and INCAGN02390 for First-Line Treatment in Patients with PD-L1 Positive Recurrent/Metastatic Head and Neck Cancer
- Disease:Squamous cell carcinoma of head and neck
- Substances:RetifanlimabTuparstobart+1
Spain- Participants:18–64 years · 65+ years
- Substances:Retifanlimab
- Sponsor:Incyte Biosciences International S.a.r.l.











